CASE REPORT article
Front. Oncol.
Sec. Thoracic Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1632133
This article is part of the Research TopicInnovative Drug Combinations for Enhanced Solid Tumor Treatment EfficacyView all 11 articles
Etoposide and Cisplatin in combination with Anlotinib for lung NUT cancer: a case report
Provisionally accepted
- 1Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
- 2Three Gorges University, No. 8 University Road, Yichang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Lung NUT carcinoma is a rare malignant tumor, which is highly aggressive, poorly differentiated, and difficult to recognize at an early stage, and is associated with very rare reports and extremely poor prognosis, with some reports showing a mOS of only 2.2 months. In this paper, we report the treatment of a rare case of primary lung NUT cancer. After surgery, chemotherapy and targeted therapy, the patient's progression-free survival is now more than 4 months, which provides a feasible treatment option for lung NUT cancer.
Keywords: lung NUT carcinoma, NUT midline carcinoma, chemotherapy, Anlotinib, targeted therapy, case report
Received: 18 Jun 2025; Accepted: 28 Aug 2025.
Copyright: © 2025 Xing, Zhang, Bian and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Tong Zhang, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.